Showing results (2631-2640 of 3,717) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|June 29, 2019
Evaluation of absorption, distribution, metabolism, and excretion of [14C]-rucaparib, a poly(ADP-ribose) polymerase inhibitor, in patients with advanced solid tumorsMingxiang Liao, Simon Watkins, Eileen Nash, et al.
Investigational New Drugs|June 30, 2019
Vitamin K3 thio-derivative: a novel specific apoptotic inducer in the doxorubicin-sensitive and -resistant cancer cellsMohamed-Elamir F Hegazy, Masashi Fukaya, Mona Dawood, et al.
Investigational New Drugs|October 13, 2019
Mass balance and metabolite profiling of 14C-guadecitabine in patients with advanced cancerJeroen Roosendaal, Hilde Rosing, Luc Lucas, et al.
Investigational New Drugs|October 16, 2019
Discovery and evaluation of Atopaxar hydrobromide, a novel JAK1 and JAK2 inhibitor, selectively induces apoptosis of cancer cells with constitutively activated STAT3Jingjie Sun, Yuping Du, Xinxin Zhang, et al.
Investigational New Drugs|July 4, 2019
LncRNA differentiation antagonizing non-protein coding RNA promotes proliferation and invasion through regulating miR-135a/NLRP37 axis in pancreatic cancerYong Tang, Guojun Cao, Gang Zhao, et al.
Investigational New Drugs|March 3, 2010
Thioredoxin reductase inhibitor ethaselen increases the drug sensitivity of the colon cancer cell line LoVo towards cisplatin via regulation of G1 phase and reversal of G2/M phase arrestJia-Ning Fu, Jing Li, Qiang Tan, et al.
Investigational New Drugs|January 1, 1986
Comparison of the colony forming ability and invasive potential of six primate cell lines treated with retinoic acidT Saiga, D E Wierenga, I Levenbook, et al.
Investigational New Drugs|January 1, 1986
Novantrone for childhood malignant solid tumors. A pediatric oncology group phase II studyC B Pratt, T J Vietti, E Etcubanas, et al.
Investigational New Drugs|January 1, 1986
A phase II study of dihydroxyanthracenedione (DHAD, mitoxantrone, NSC 301739) in advanced malignant melanomaJ C Arseneau, D A Schoenfeld, E C Borden
Investigational New Drugs|March 18, 2015
Phase I study of the anti-MET antibody onartuzumab in patients with solid tumors and MET-positive lung cancerMakoto Nishio, Atsushi Horiike, Hiroshi Nokihara, et al.
Pageof 372